272
Views
10
Downloads
0
Crossref
N/A
WoS
0
Scopus
N/A
CSCD
The wide use of antibody‐drug conjugates (ADCs) is transforming the cancer‐treatment landscape. Understanding the treatment‐related adverse events (AEs) of ADCs is crucial for their clinical application. We conducted a meta‐analysis to analyze the profile and incidence of AEs related to ADC use in the treatment of solid tumors and hematological malignancies.
We searched the PubMed, Embase, and Cochrane Library databases for articles published from January 2001 to October 2022. The overall profile and incidence of all‐grade and grade ≥ 3 treatment‐related AEs were the primary outcomes of the analysis.
A total of 138 trials involving 15,473 patients were included in this study. The overall incidence of any‐grade treatment‐related AEs was 100.0% (95% confidence interval [CI]: 99.9%–100.0%; I2 = 89%) and the incidence of grade ≥ 3 treatment‐related AEs was 6.2% (95% CI: 3.0%–12.4%; I² = 99%).
This study provides a comprehensive overview of AEs related to ADCs used for cancer treatment. ADC use resulted in a high incidence of any‐grade AEs but a low incidence of grade ≥ 3 AEs. The AE profiles and incidence differed according to cancer type, ADC type, and ADC components.
The wide use of antibody‐drug conjugates (ADCs) is transforming the cancer‐treatment landscape. Understanding the treatment‐related adverse events (AEs) of ADCs is crucial for their clinical application. We conducted a meta‐analysis to analyze the profile and incidence of AEs related to ADC use in the treatment of solid tumors and hematological malignancies.
We searched the PubMed, Embase, and Cochrane Library databases for articles published from January 2001 to October 2022. The overall profile and incidence of all‐grade and grade ≥ 3 treatment‐related AEs were the primary outcomes of the analysis.
A total of 138 trials involving 15,473 patients were included in this study. The overall incidence of any‐grade treatment‐related AEs was 100.0% (95% confidence interval [CI]: 99.9%–100.0%; I2 = 89%) and the incidence of grade ≥ 3 treatment‐related AEs was 6.2% (95% CI: 3.0%–12.4%; I² = 99%).
This study provides a comprehensive overview of AEs related to ADCs used for cancer treatment. ADC use resulted in a high incidence of any‐grade AEs but a low incidence of grade ≥ 3 AEs. The AE profiles and incidence differed according to cancer type, ADC type, and ADC components.
Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, et al. Antibody‐drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72(2):165–182. https://doi.org/10.3322/caac.21705
Chau CH, Steeg PS, Figg WD. Antibody‐drug conjugates for cancer. Lancet. 2019;394(10200):793–804. https://doi.org/10.1016/S0140-6736(19)31774-X
Chia CSB. A patent review on FDA‐approved antibody‐drug conjugates, their linkers and drug payloads. ChemMedChem. 2022;17(11):e202200032. https://doi.org/10.1002/cmdc.202200032
Deeks ED. Disitamab vedotin: first approval. Drugs. 2021;81(16):1929–1935. https://doi.org/10.1007/s40265-021-01614-x
Dhillon S. Moxetumomab pasudotox: first global approval. Drugs. 2018;78(16):1763–1767. https://doi.org/10.1007/s40265-018-1000-9
Gomes‐da‐Silva LC, Kepp O, Kroemer G. Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death. Oncoimmunology. 2020;9(1):1841393. https://doi.org/10.1080/2162402X.2020.1841393
Professional Committee on Clinical Research of Oncology Drugs, Chinese Anti‐Cancer Association, Expert Committee for Monitoring the Clinical Application of Antitumor Drugs, Breast Cancer Expert Committee of National Cancer Quality Control Center, Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center. Expert consensus on the clinical application of antibody‐drug conjugates in the treatment of malignant tumors (2021 edition). Cancer Innovation. 2022;1(1):3–24. https://doi.org/10.1002/cai2.8
Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody‐drug conjugates. Mabs. 2016;8(4):659–671. https://doi.org/10.1080/19420862.2016.1156829
Wolska‐Washer A, Robak T. Safety and tolerability of antibody‐drug conjugates in cancer. Drug Saf. 2019;42(2):295–314. https://doi.org/10.1007/s40264-018-0775-7
Makawita S, Meric‐Bernstam F. Antibody‐drug conjugates: patient and treatment selection. Am Soc Clin Oncol Educ Book. 2020;40:105–114. https://doi.org/10.1200/EDBK_280775
Conte P, Ascierto PA, Patelli G, Danesi R, Vanzulli A, Sandomenico F, et al. Drug‐induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open. 2022;7(2):100404. https://doi.org/10.1016/j.esmoop.2022.100404
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097
Zhou X, Yao Z, Bai H, Duan J, Wang Z, Wang X, et al. Treatment‐related adverse events of PD‐1 and PD‐L1 inhibitor‐based combination therapies in clinical trials: a systematic review and meta‐analysis. Lancet Oncol. 2021;22(9):1265–1274. https://doi.org/10.1016/S1470-2045(21)00333-8
Lin L, Chu H. Meta‐analysis of proportions using generalized linear mixed models. Epidemiology. 2020;31(5):713–717. https://doi.org/10.1097/EDE.0000000000001232
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ. 2003;327(7414):557–560. https://doi.org/10.1136/bmj.327.7414.557
Hunter JP, Saratzis A, Sutton AJ, Boucher RH, Sayers RD, Bown MJ. In meta‐analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. JCE. 2014;67(8):897–903. https://doi.org/10.1016/j.jclinepi.2014.03.003
Egger M, Smith GD, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. https://doi.org/10.1136/bmj.315.7109.629
Wang J, Xu B, Wang W, Fang J. An open‐label, dose‐escalation phase Ⅰ study to evaluate RC48‐ADC, a novel antibody‐drug conjugate, in patients with HER2‐positive metastatic breast cancer. J Clin Oncol. 2018;36(15_suppl):1030. https://doi.org/10.1200/JCO.2018.36.15_suppl.1030
Xu Y, Wang Y, Gong J, Zhang X, Peng Z, Sheng X, et al. Phase Ⅰ study of the recombinant humanized anti‐HER2 monoclonal antibody–MMAE conjugate RC48‐ADC in patients with HER2‐positive advanced solid tumors. Gastric Cancer. 2021;24(4):913–925. https://doi.org/10.1007/s10120-021-01168-7
Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, et al. Open‐label, multicenter, phase Ⅱ study of RC48‐ADC, a HER2‐targeting antibody‐drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2021;27(1):43–51. https://doi.org/10.1158/1078-0432.CCR-20-2488
Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, et al. Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase Ⅱ study. Cancer Commun. 2021;41(11):1173–1182. https://doi.org/10.1002/cac2.12214
Sheng X, He Z, Shi Y, Luo H, Han W, Yao X, et al. RC48‐ADC for metastatic urothelial carcinoma with HER2‐positive: combined analysis of RC48‐C005 and RC48‐C009 trials. J Clin Oncol. 2022;40(16_suppl):4520. https://doi.org/10.1200/JCO.2022.40.16_suppl.4520
Xu H, Sheng X, Yan X, Chi Z, Cui C, Si L, et al. A phase Ⅱ study of RC48‐ADC in HER2‐negative patients with locally advanced or metastatic urothelial carcinoma. J Clin Oncol. 2020;38(15_suppl):e17113. https://doi.org/10.1200/JCO.2020.38.15_suppl.e17113
Gong J, Shen L, Wang W, Fang J. Safety, pharmacokinetics and efficacy of RC48‐ADC in a phase Ⅰ study in patients with HER2‐overexpression advanced solid cancer. J Clin Oncol. 2018;36(15_suppl):e16059. https://doi.org/10.1200/JCO.2018.36.15_suppl.e16059
Sheng X, He Z, Han W, Zhou AP, Luo H, Shi Y, et al. An open‐label, single‐arm, multicenter, phase Ⅱ study of RC48‐ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48‐C009). J Clin Oncol. 2021;39(15_suppl):4584. https://doi.org/10.1200/JCO.2021.39.15_suppl.4584
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2‐Low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. https://doi.org/10.1056/NEJMoa2203690
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2‐positive gastric cancer. N Engl J Med. 2020;382(25):2419–2430. https://doi.org/10.1056/NEJMoa2004413
Tsurutani J, Iwata H, Krop I, Jänne PA, Doi T, Takahashi S, et al. Targeting HER2 with trastuzumab deruxtecan: a dose‐expansion, phase Ⅰ study in multiple advanced solid tumors. Cancer Discov. 2020;10(5):688–701. https://doi.org/10.1158/2159-8290.CD-19-1014
Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, et al. Trastuzumab deruxtecan in HER2‐mutant non–small‐cell lung cancer. N Engl J Med. 2022;386(3):241–251. https://doi.org/10.1056/NEJMoa2112431
Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, et al. Trastuzumab deruxtecan (DS‐8201a) in patients with advanced HER2‐positive gastric cancer: a dose‐expansion, phase 1 study. Lancet Oncol. 2019;20(6):827–836. https://doi.org/10.1016/S1470-2045(19)30088-9
Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, et al. Trastuzumab deruxtecan (DS‐8201) in patients with HER2‐expressing metastatic colorectal cancer (DESTINY‐CRC01): a multicentre, open‐label, phase 2 trial. Lancet Oncol. 2021;22(6):779–789. https://doi.org/10.1016/S1470-2045(21)00086-3
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143–1154. https://doi.org/10.1056/NEJMoa2115022
Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider‐Schur S, et al. Trastuzumab deruxtecan in HER2‐positive breast cancer with brain metastases: a single‐arm, phase 2 trial. Nature Med. 2022;28(9):1840–1847. https://doi.org/10.1038/s41591-022-01935-8
Diéras V, Deluche E, Lusque A, Pistilli B, Bachelot T, Pierga JY, et al. Abstract PD8‐02: trastuzumab deruxtecan (T‐DXd) for advanced breast cancer patients (ABC), regardless HER2 status: a phase Ⅱ study with biomarkers analysis (DAISY. Cancer Res. 2022;82(4_Suppl):PD8‐02. https://doi.org/10.1158/1538-7445.SABCS21-PD8-02
Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2‐low–expressing advanced breast cancer: results from a phase Ⅰb study. J Clin Oncol. 2020;38(17):1887–1896. https://doi.org/10.1200/JCO.19.02318
Bando H, Kinoshita I, Modi S, Tsurutani J, Bang YJ, Iwata H, et al. Trastuzumab deruxtecan (T‐DXd) in patients with human epidermal growth factor receptor 2 (HER2)‐expressing salivary duct carcinoma: subgroup analysis of two phase 1 studies. J Clin Oncol. 2021;39(15_suppl):6079. https://doi.org/10.1200/JCO.2021.39.15_suppl.6079
Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, et al. Trastuzumab deruxtecan (DS‐8201a) in patients with advanced HER2‐positive breast cancer previously treated with trastuzumab emtansine: a dose‐expansion, phase 1 study. Lancet Oncol. 2019;20(6):816–826. https://doi.org/10.1016/S1470-2045(19)30097-X
Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, et al. Multicenter phase Ⅱ trial of trastuzumab deruxtecan for HER2‐positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncol. 2022;18(19):2351–2360. https://doi.org/10.2217/fon-2022-0214
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2‐positive breast cancer. N Engl J Med. 2020;382(7):610–621. https://doi.org/10.1056/NEJMoa1914510
Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, et al. Correction to: trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first‐line or second‐line treatment for HER2‐positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non‐inferiority, phase Ⅲ trial in Japan (JBCRG‐M06/EMERALD). Trials. 2020;21(1):503. https://doi.org/10.1186/s13063-020-04408-w
Beeram M, Krop IE, Burris HA, Girish SR, Yu W, Lu MW, et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2‐positive breast cancer. Cancer. 2012;118(23):5733–5740. https://doi.org/10.1002/cncr.27622
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, et al. Ado‐trastuzumab emtansine for patients with HER2‐mutant lung cancers: results from a phase Ⅱ basket trial. J Clin Oncol. 2018;36(24):2532–2537. https://doi.org/10.1200/jco.2017.35.15_suppl.8510
Hotta K, Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, et al. A phase Ⅱ study of trastuzumab emtansine in HER2‐positive non‐small cell lung cancer. J Thorac Oncol. 2018;13(2):273–279. https://doi.org/10.1016/j.jtho.2017.10.032
Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, et al. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage Ⅰ HER2‐positive breast cancer (ATEMPT): a randomized clinical trial. J Clin Oncol. 2021;39(21):2375–2385. https://doi.org/10.1200/JCO.20.03398
Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, et al. Phase Ⅱ randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2‐positive metastatic breast cancer. J Clin Oncol. 2013;31(9):1157–1163. https://doi.org/10.1200/JCO.2012.44.9694
Yamamoto H, Ando M, Aogi K, Iwata H, Tamura K, Yonemori K, et al. Phase Ⅰ and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2‐positive metastatic breast cancer. Jpn J Clin Oncol. 2015;45(1):12–18. https://doi.org/10.1093/jjco/hyu160
Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, et al. Phase Ⅰ study of trastuzumab‐DM1, an HER2 antibody‐drug conjugate, given every 3 weeks to patients with HER2‐positive metastatic breast cancer. J Clin Oncol. 2010;28(16):2698–2704. https://doi.org/10.1200/JCO.2009.26.2071
Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase Ⅱ study of the antibody drug conjugate trastuzumab‐DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)‐positive breast cancer after prior HER2‐directed therapy. J Clin Oncol. 2011;29(4):398–405. https://doi.org/10.1200/JCO.2010.29.5865
Montemurro F, Ellis P, Anton A, Wuerstlein R, Delaloge S, Bonneterre J, et al. Safety of trastuzumab emtansine (T‐DM1)in patients with HER2‐positive advanced breast cancer: primary results from the KAMILLA study cohort 1. Eur J Cancer. 2019;109:92–102. https://doi.org/10.1016/j.annonc.2020.06.020
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2‐positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. https://doi.org/10.1056/nejmoa1209124
Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, et al. Trastuzumab emtansine (T‐DM1) in patients with previously treated HER2‐overexpressing metastatic non‐small cell lung cancer: efficacy, safety, and biomarkers. Clin Cancer Res. 2019;25(1):64–72. https://doi.org/10.1158/1078-0432.ccr-18-1590
Iwama E, Zenke Y, Sugawara S, Daga H, Morise M, Yanagitani N, et al. Trastuzumab emtansine for patients with non‐small cell lung cancer positive for human epidermal growth factor receptor 2 exon‐20 insertion mutations. Eur J Cancer. 2022;162:99–106. https://doi.org/10.1016/j.ejca.2021.11.021
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2‐positive breast cancer. N Engl J Med. 2019;380(7):617–628. https://doi.org/10.1056/nejmoa1814017
Krop IE, Kim SB, González‐Martín A, LoRusso PM, Ferrero JM, Smitt M, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2‐positive advanced breast cancer (TH3RESA): a randomised, open‐label, phase 3 trial. Lancet Oncol. 2014;15(7):689–699. https://doi.org/10.1016/s1470-2045(14)70178-0
Thuss‐Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2‐positive locally advanced or metastatic gastric or gastro‐oesophageal junction adenocarcinoma (GATSBY): an international randomised, open‐label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640–653. https://doi.org/10.1016/s1470-2045(17)30111-0
Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2‐positive advanced breast cancer: final results from MARIANNE. Cancer. 2019;125(22):3974–3984. https://doi.org/10.1200/jco.2016.67.4887
Krop IE, Suter TM, Dang CT, Dirix L, Romieu G, Zamagni C, et al. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline‐based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2‐positive early‐stage breast cancer. J Clin Oncol. 2015;33(10):1136–1142. https://doi.org/10.1200/JCO.2014.58.7782
Brivio E, Locatelli F, Lopez‐Yurda M, Malone A, Díaz‐de‐Heredia C, Bielorai B, et al. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC‐059 study). Blood. 2021;137(12):1582–1590. https://doi.org/10.1182/blood.2020009407
Goy A, Forero A, Wagner‐Johnston N, Christopher Ehmann W, Tsai M, Hatake K, et al. A phase 2 study of inotuzumab ozogamicin in patients with indolent B‐cell non‐Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. Br J Haematol. 2016;174(4):571–581. https://doi.org/10.1111/bjh.14094
Pennesi E, Michels N, Brivio E, vander Velden VHJ, Jiang Y, Thano A, et al. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase Ⅱ trial. Leukemia. 2022;36(6):1516–1524. https://doi.org/10.1038/s41375-022-01576-3
Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, et al. Inotuzumab ozogamicin, an anti‐CD22‐calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403–411. https://doi.org/10.1016/s1470-2045(11)70386-2
Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–753. https://doi.org/10.1056/nejmoa1509277
DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22‐positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1(15):1167–1180. https://doi.org/10.1182/bloodadvances.2016001925
Ogura M, Tobinai K, Hatake K, Uchida T, Kasai M, Oyama T, et al. Phase Ⅰ study of inotuzumab ozogamicin (CMC‐544) in Japanese patients with follicular lymphoma pretreated with rituximab‐based therapy. Cancer Sci. 2010;101(8):1840–1845. https://doi.org/10.1111/j.1349-7006.2010.01601.x
Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728–2736. https://doi.org/10.1002/cncr.28136
Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study. Cancer. 2019;125(14):2474–2487. https://doi.org/10.1002/cncr.32116
Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open‐label, randomised, phase 3 INO‐VATE study. Lancet Haematology. 2017;4(8):e387–e398. https://doi.org/10.1016/s2352-3026(17)30103-5
DeAngelo DJ, Advani AS, Marks DI, Stelljes M, Liedtke M, Stock W, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020;10(8):81. https://doi.org/10.1038/s41408-020-00345-8
de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first‐in‐human, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(3):383–393. https://doi.org/10.1016/s1470-2045(18)30859-3
Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin Cancer Res. 2020;26(6):1220–1228. https://doi.org/10.1158/1078-0432.ccr-19-2962
Coleman RL, Lorusso D, Gennigens C, González‐Martín A, Randall L, Cibula D, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG‐3023/ENGOT‐cx6): a multicentre, open‐label, single‐arm, phase 2 study. Lancet Oncol. 2021;22(5):609–619. https://doi.org/10.1016/s1470-2045(21)00056-5
Yonemori K, Kuboki Y, Hasegawa K, Iwata T, Kato H, Takehara K, et al. Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: results from the innovaTV 206 study. Cancer Sci. 2022;113(8):2788–2797. https://doi.org/10.1111/cas.15443
Hong DS, Birnbaum A, Steuer C, Taylor M, George TJ, Lacy J, et al. Efficacy and safety of tisotumab vedotin in patients with head and neck squamous cell carcinoma: results from a phase Ⅱ cohort. Int J Radiat Oncol*Biol*Phys. 2022;112(5):e10–e11. https://doi.org/10.1016/j.ijrobp.2021.12.028
Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab govitecan‐hziy in refractory metastatic triple‐negative breast cancer. N Engl J Med. 2019;380(8):741–751. https://doi.org/10.1056/nejmoa1814213
Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, et al. Efficacy and safety of anti‐trop‐2 antibody drug conjugate sacituzumab govitecan (IMMU‐132) in heavily pretreated patients with metastatic triple‐negative breast cancer. J Clin Oncol. 2017;35(19):2141–2148. https://doi.org/10.1200/JCO.2016.70.8297
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple‐negative breast cancer. N Engl J Med. 2021;384(16):1529–1541. https://doi.org/10.1056/nejmoa2028485
Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, et al. Sacituzumab govitecan, a Trop‐2‐directed antibody‐drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase Ⅰ/Ⅱ IMMU‐132‐01 basket trial. Ann Oncol. 2021;32(6):746–756. https://doi.org/10.1016/j.annonc.2021.03.005
Carey LA, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, et al. Sacituzumab govitecan as second‐line treatment for metastatic triple‐negative breast cancer‐phase 3 ASCENT study subanalysis. NPJ Breast Cancer. 2022;8(1):72. https://doi.org/10.1038/s41523-022-00439-5
O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, et al. Analysis of patients without and with an initial triple‐negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple‐negative breast cancer. Breast Cancer Res Treat. 2022;195(2):127–139. http://doi.org/10.1007/s10549-022-06602-7
Santin A, Komiya T, Goldenberg DM, Sharkey RM, Hong Q, Wegener WA, et al. Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase Ⅰ/Ⅱ study. J Clin Oncol. 2020;38(15_suppl):6081. https://doi.org/10.1200/JCO.2020.38.15_suppl.6081
Marmé F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, et al. 58O safety interim analysis (SIA) of the phase Ⅲ postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2‐negative breast cancer (BC) at high relapse risk after neoadjuvant treatment. Ann Oncol. 2022;33:S148–S149. https://doi.org/10.1016/j.annonc.2022.03.074
Spring L, Tolaney SM, Desai NV, Fell G, Trippa L, Comander AH, et al. Phase 2 study of response‐guided neoadjuvant sacituzumab govitecan (IMMU‐132) in patients with localized triple‐negative breast cancer: results from the NeoSTAR trial. J Clin Oncol. 2022;40(16_suppl):512. https://doi.org/10.1200/JCO.2022.40.16_suppl.512
Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O'Shaughnessy J, et al. Sacituzumab govitecan in previously treated hormone receptor‐positive/HER2‐negative metastatic breast cancer: final results from a phase Ⅰ/Ⅱ, single‐arm, basket trial. Ann Oncol. 2020;31(12):1709–1718. https://doi.org/10.1016/j.annonc.2020.09.004
Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fléchon A, et al. TROPHY‐U‐01: a phase Ⅱ open‐label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum‐based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474–2485. https://doi.org/10.1200/JCO.20.03489
Palanca‐Wessels MCA, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, et al. Safety and activity of the anti‐CD79B antibody‐drug conjugate polatuzumab vedotin in relapsed or refractory B‐cell non‐hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704–715. https://doi.org/10.1016/s1470-2045(15)70128-2
Takahashi S, Uemura M, Kimura T, Kawasaki Y, Takamoto A, Yamaguchi A, et al. A phase Ⅰ study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma. Invest New Drugs. 2020;38(4):1056–1066. https://doi.org/10.1007/s10637-019-00844-x
Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, et al. Enfortumab vedotin after PD‐1 or PD‐L1 inhibitors in cisplatin‐ineligible patients with advanced urothelial carcinoma (EV‐201): a multicentre, single‐arm, phase 2 trial. Lancet Oncol. 2021;22(6):872–882. https://doi.org/10.1016/s1470-2045(21)00094-2
Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125–1135. https://doi.org/10.1056/nejmoa2035807
Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, et al. EV‐101: a phase Ⅰ study of single‐agent enfortumab vedotin in patients with nectin‐4‐positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol. 2020;38(10):1041–1049. https://doi.org/10.1200/JCO.19.02044
Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti‐programmed death 1/programmed death ligand 1 therapy. J Clin Oncol. 2019;37(29):2592–2600. https://doi.org/10.1200/JCO.19.01140
Friedlander TW, Milowsky MI, Bilen MA, Srinivas S, McKay RR, Flaig TW, et al. Study EV‐103: update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC). J Clin Oncol. 2021;39(15_suppl):4528. https://doi.org/10.1200/JCO.2021.39.15_suppl.4528
McGregor BA, Balar AV, Rosenberg JE, Van Der Heijden MS, Park SH, Lee JL, et al. Enfortumab vedotin in cisplatin‐ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD‐1/PD‐L1 inhibitors: an updated analysis of EV‐201 cohort 2. J Clin Oncol. 2021;39(15_suppl):4524. https://doi.org/10.1200/JCO.2021.39.15_suppl.4524
Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018;32(8):1768–1777. https://doi.org/10.1038/s41375-018-0210
Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler‐Stevenson M, et al. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long‐term follow‐up. Blood. 2018;131(21):2331–2334. https://doi.org/10.1182/blood-2017-09-803072
Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, et al. A phase Ⅰ study of moxetumomab pasudotox in adults with relapsed or refractory B‐cell acute lymphoblastic leukaemia. Br J Haematol. 2018;182(3):442–444. https://doi.org/10.1111/bjh.14806
Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Robak T, Le Coutre PD, et al. Moxetumomab pasudotox in heavily pre‐treated patients with relapsed/refractory hairy cell leukemia (HCL): long‐term follow‐up from the pivotal trial. J Hematol Oncol. 2021;14(1):35. https://doi.org/10.1186/s13045-020-01004-y
Shah NN, Bhojwani D, August K, Baruchel A, Bertrand Y, Boklan J, et al. Results from an international phase 2 study of the anti‐CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B‐lineage acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67(5):e28112. https://doi.org/10.1002/pbc.28112
Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler‐Stevenson M, et al. Phase Ⅰ trial of anti‐CD22 recombinant immunotoxin moxetumomab pasudotox (CAT‐8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012;30(15):1822–1828. https://doi.org/10.1200/JCO.2011.38.1756
Wayne AS, Shah NN, Bhojwani D, Silverman LB, Whitlock JA, Stetler‐Stevenson M, et al. Phase 1 study of the anti‐CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. Blood. 2017;130(14):1620–1627. https://doi.org/10.1182/blood-2017-02-749101
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM‐2): a two‐arm, randomised, open‐label, phase 2 study. Lancet Oncol. 2020;21(2):207–221. https://doi.org/10.1016/S1470-2045(19)30788-0
Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Antibody‐drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase Ⅰ study. Blood Cancer J. 2019;9(4):37. https://doi.org/10.1038/s41408-019-0196-6
Tzogani K, Penttilä K, Lähteenvuo J, Lapveteläinen T, Lopez Anglada L, Prieto C, et al. EMA review of belantamab mafodotin (blenrep) for the treatment of adult patients with relapsed/refractory multiple myeloma. Oncologist. 2021;26(1):70–76. https://doi.org/10.1002/onco.13592
Lonial S, Nooka AK, Thulasi P, Badros AZ, Jeng BH, Callander NS, et al. Management of belantamab mafodotin‐associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J. 2021;11(5):103. https://doi.org/10.1038/s41408-021-00494-4
Richardson PG, Lee HC, Abdallah AO, Cohen AD, Kapoor P, Voorhees PM, et al. Single‐agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM‐2 study. Blood Cancer J. 2020;10(10):106. https://doi.org/10.1038/s41408-020-00369-0
Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Targeting B‐cell maturation antigen with GSK2857916 antibody‐drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19(12):1641–1653. https://doi.org/10.1016/S1470-2045(18)30576-X
Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B‐cell lymphoma (LOTIS‐2): a multicentre, open‐label, single‐arm, phase 2 trial. Lancet Oncol. 2021;22(6):790–800. https://doi.org/10.1016/S1470-2045(21)00139-X
Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, et al. Loncastuximab tesirine, an anti‐CD19 antibody‐drug conjugate, in relapsed/refractory B‐cell acute lymphoblastic leukemia. Blood Adv. 2020;4(3):449–457. https://doi.org/10.1182/bloodadvances.2019000767
Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess BT, et al. Efficacy and safety of loncastuximab tesirine (ADCT‐402) in relapsed/refractory diffuse large B‐cell lymphoma. Blood. 2020;136:35–37. https://doi.org/10.1182/blood-2020-137524
Kahl BS, Hamadani M, Radford J, Carlo‐Stella C, Caimi P, Reid E, et al. A phase Ⅰ study of ADCT‐402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine‐based antibody‐drug conjugate, in relapsed/refractory B‐cell non‐hodgkin lymphoma. Clin Cancer Res. 2019;25(23):6986–6994. https://doi.org/10.1158/1078-0432.CCR-19-0711
Hamadani M, Radford J, Carlo‐Stella C, Caimi PF, Reid E, O'Connor OA, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B‐cell non‐hodgkin lymphoma. Blood. 2021;137(19):2634–2645. https://doi.org/10.1182/blood.2020007512
Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase iii eortc‐gimema aml‐19 trial. J Clin Oncol. 2016;34(9):972–979. https://doi.org/10.1200/JCO.2015.64.0060
Amadori S, Suciu S, Stasi R, Willemze R, Mandelli F, Selleslag D, et al. Gemtuzumab ozogamicin (Mylotarg) as single‐agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML‐15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia. 2005;19(10):1768–1773. https://doi.org/10.1038/sj.leu.2403901
Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33‐positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther. 2001;1(5):893–901. https://doi.org/10.1517/14712598.1.5.893
Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, Isidori A, et al. Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leuk Lymphoma. 2004;45(9):1791–1795. https://doi.org/10.1080/1042819042000219485
Lo‐Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 2004;104(7):1995–1999. https://doi.org/10.1182/blood-2004-04-1550
Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442–1452. https://doi.org/10.1002/cncr.21326
Zwaan CM, Reinhardt D, Zimmerman M, Hasle H, Stary J, Stark B, et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase Ⅱ study. Br J Haematol. 2010;148(5):768–776. https://doi.org/10.1111/j.1365-2141.2009.08011.x
Nabhan C, Rundhaugen LM, Riley MB, Rademaker A, Boehlke L, Jatoi M, et al. Phase Ⅱ pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leuk Res. 2005;29(1):53–57. https://doi.org/10.1016/j.leukres.2004.04.011
Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood. 2005;106(4):1183–1188. https://doi.org/10.1182/blood-2004-10-3821
Wang ES, Aplenc R, Chirnomas D, Dugan M, Fazal S, Iyer S, et al. Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded‐access protocol for patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2020;61(8):1965–1973. https://doi.org/10.1080/10428194.2020.1742897
Taksin AL, Legrand O, Raffoux E, De Revel T, Thomas X, Contentin N, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the Alfa group. Leukemia. 2007;21(1):66–71. https://doi.org/10.1038/sj.leu.2404434
Kobayashi Y, Tobinai K, Takeshita A, Naito K, Asai O, Dobashi N, et al. Phase Ⅰ/Ⅱ study of humanized anti‐CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study. Int J Hematol. 2009;89(4):460–469. https://doi.org/10.1007/s12185-009-0298-1
Kim YH, Tavallaee M, Sundram U, Salva KA, Wood GS, Li S, et al. Phase Ⅱ investigator‐initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi‐institution collaborative project. J Clin Oncol. 2015;33(32):3750–3758. https://doi.org/10.1200/JCO.2014.60.3969
Forero‐Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126(26):2798–2804. https://doi.org/10.1182/blood-2015-06-644336
Ogura M, Tobinai K, Hatake K, Ishizawa K, Uike N, Uchida T, et al. Phase Ⅰ/Ⅱ study of brentuximab vedotin in J apanese patients with relapsed or refractory CD 30‐positive H odgkin's lymphoma or systemic anaplastic large‐cell lymphoma. Cancer Sci. 2014;105(7):840–846. https://doi.org/10.1111/cas.12435
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem‐cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double‐blind, placebo‐controlled, phase 3 trial. The Lancet. 2015;385(9980):1853–1862. https://doi.org/10.1016/S0140-6736(15)60165-9
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician's choice in CD30‐positive cutaneous T‐cell lymphoma (ALCANZA): an international, open‐label, randomised, phase 3, multicentre trial. The Lancet. 2017;390(10094):555–566. https://doi.org/10.1016/S0140-6736(17)31266-7
Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow‐up of the multicohort single‐arm phase Ⅱ CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428–1439. https://doi.org/10.1200/JCO.2017.76.0793
Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz‐Kozik E, Gasiorowski R, Johnson NA, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE‐204): an interim analysis of a multicentre, randomised, open‐label, phase 3 study. Lancet Oncol. 2021;22(4):512–524. https://doi.org/10.1016/S1470-2045(21)00005-X
Walewski J, Hellmann A, Siritanaratkul N, Ozsan GH, Ozcan M, Chuncharunee S, et al. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi‐agent chemotherapy. Br J Haematol. 2018;183(3):400–410. https://doi.org/10.1111/bjh.15539
Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, et al. Results of a multicenter phase Ⅱ trial of brentuximab vedotin as second‐line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136–2140. https://doi.org/10.1016/j.bbmt.2015.07.018
Sharman JP, Wheler JJ, Einhorn L, Dowlati A, Shapiro GI, Hilton J, et al. A phase 2, open‐label study of brentuximab vedotin in patients with CD30‐expressing solid tumors. Invest New Drugs. 2019;37(4):738–747. https://doi.org/10.1007/s10637-019-00768-6
Gotlib J, Baird JH, George TI, Langford C, Reyes I, Abuel J, et al. A phase 2 study of brentuximab vedotin in patients with CD30‐positive advanced systemic mastocytosis. Blood Adv. 2019;3(15):2264–2271. https://doi.org/10.1182/bloodadvances.2019000152
Fanale MA, Forero‐Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, et al. A phase Ⅰ weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30‐positive hematologic malignancies. Clin Cancer Res. 2012;18(1):248–255. https://doi.org/10.1158/1078-0432.CCR-11-1425
Kim M, Lee JO, Koh J, Kim TM, Lee JY, Jeon YK, et al. A phase Ⅱ study of brentuximab vedotin in patients with relapsed or refractory Epstein‐Barr virus‐positive and CD30‐positive lymphomas. Haematologica. 2021;106(8):2277–2280. https://doi.org/10.3324/haematol.2021.278301
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN‐35) in patients with relapsed or refractory systemic anaplastic large‐cell lymphoma: results of a phase Ⅱ study. J Clin Oncol. 2012;30(18):2190–2196. https://doi.org/10.1200/JCO.2011.38.0402
Song Y, Guo Y, Huang H, Li W, Ke X, Feng J, et al. Phase Ⅱ single‐arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Expert Rev Hematol. 2021;14(9):867–875. https://doi.org/10.1080/17474086.2021.1942831
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN‐35) for relapsed CD30‐positive lymphomas. N Engl J Med. 2010;363(19):1812–1821. https://doi.org/10.1056/NEJMoa1002965
Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–1402. https://doi.org/10.1182/blood-2014-09-598763
Locatelli F, Mauz‐Koerholz C, Neville K, Llort A, Beishuizen A, Daw S, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large‐cell lymphoma: a multicentre, open‐label, phase 1/2 study. Lancet Haematol. 2018;5(10):e450–e461. https://doi.org/10.1016/S2352-3026(18)30153-4
Stefoni V, Marangon M, Re A, Lleshi A, Bonfichi M, Pinto A, et al. Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase Ⅱ study of FIL ONLUS. Haematologica. 2020;105(10):e512. https://doi.org/10.3324/haematol.2019.243170
Forero‐Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, et al. Brentuximab vedotin in transplant‐naïve patients with relapsed or refractory Hodgkin lymphoma: analysis of two phase Ⅰ studies. Oncologist. 2012;17(8):1073–1080. https://doi.org/10.1634/theoncologist.2012-0133
Zhao B, Chen R, O'Connor OA, Gopal AK, Ramchandren R, Goy A, et al. Brentuximab vedotin, an antibody‐drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment. Br J Clin Pharmacol. 2016;82(3):696–705. https://doi.org/10.1111/bcp.12988
Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(8):1236–1243. https://doi.org/10.1182/blood-2014-08-595801
Kim SJ, Yoon DH, Kim JS, Kang HJ, Lee HW, Eom HS, et al. Efficacy of brentuximab vedotin in relapsed or refractory high‐CD30‐expressing non‐hodgkin lymphomas: results of a multicenter, open‐labeled phase Ⅱ trial. Cancer Res Treat. 2020;52(2):374–387. https://doi.org/10.4143/crt.2019.198
Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Five‐year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562–1566. https://doi.org/10.1182/blood-2016-02-699850
Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five‐year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–2642. https://doi.org/10.1182/blood-2018-07-861641
Romano A, Parrinello NL, Chiarenza A, Motta G, Tibullo D, Giallongo C, et al. Immune off‐target effects of Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. Br J Haematol. 2019;185(3):468–479. https://doi.org/10.1111/bjh.15801
DeFilipp Z, Li S, Kempner ME, Brown J, Del Rio C, Valles B, et al. Phase Ⅰ trial of brentuximab vedotin for steroid‐refractory chronic graft‐versus‐host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018;24(9):1836–1840. https://doi.org/10.1016/j.bbmt.2018.05.012
Duvic M, Tetzlaff M, Clos AL, Gangar P, Talpur R, et al. Phase Ⅱ trial of brentuximab vedotin for CD30+ cutaneous T‐cell lymphomas and lymphoproliferative disorders. Blood. 2013;122(21):367. https://doi.org/10.1182/blood.V122.21.367.367
Ashkar R, Feldman DR, Adra N, Zaid MA, Funt SA, Althouse SK, et al. Phase Ⅱ trial of brentuximab vedotin in relapsed/refractory germ cell tumors. Invest New Drugs. 2021;39(6):1656–1663. https://doi.org/10.1007/s10637-021-01134-1
Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T‐cell lymphoma: final data. Blood Adv. 2021;5(23):5098–5106. https://doi.org/10.1182/bloodadvances.2021004710
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase Ⅱ study of Brentuximab Vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183–2189. https://doi.org/10.1200/JCO.2011.38.0410
Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, et al. Retreatment with brentuximab vedotin in patients with CD30‐positive hematologic malignancies. J Hematol Oncol. 2014;7:24. https://doi.org/10.1186/1756-8722-7-24
Cognetti DM, Johnson JM, Curry JM, Kochuparambil ST, McDonald D, Mott F, et al. Phase 1/2a, open‐label, multicenter study of RM‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck. 2021;43(12):3875–3887. https://doi.org/10.1002/hed.26885
Abuhelwa Z, Alloghbi A, Nagasaka M. A comprehensive review on antibody‐drug conjugates (ADCs) in the treatment landscape of non‐small cell lung cancer (NSCLC. Cancer Treat Rev. 2022;106:102393. https://doi.org/10.1016/j.ctrv.2022.102393
Ungaro A, Tucci M, Audisio A, Di Prima L, Pisano C, Turco F, et al. Antibody‐Drug conjugates in urothelial carcinoma: a new therapeutic opportunity moves from bench to bedside. Cells. 2022;11(5):803. https://doi.org/10.3390/cells11050803
Corti C, Giugliano F, Nicolò E, Ascione L, Curigliano G. Antibody‐drug conjugates for the treatment of breast cancer. Cancers. 2021;13(12):2898. https://doi.org/10.3390/cancers13122898
Perrotti V, Caponio VCA, Mascitti M, Lo Muzio L, Piattelli A, Rubini C, et al. Therapeutic potential of antibody‐drug conjugate‐based therapy in head and neck cancer: a systematic review. Cancers. 2021;13(13):3126. https://doi.org/10.3390/cancers13133126
Masters JC, Nickens DJ, Xuan D, Shazer RL, Amantea M. Clinical toxicity of antibody drug conjugates: a meta‐analysis of payloads. Invest New Drugs. 2018;36(1):121–135. https://doi.org/10.1007/s10637-017-0520-6
Powell CA, Camidge DR, Modi S, Qin A, Taitt C, Lee C, et al. 289P risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies. Ann Oncol. 2020;31:S357–S358. https://doi.org/10.1016/j.annonc.2020.08.391
Wahab A, Rafae A, Mushtaq K, Masood A, Ehsan H, Khakwani M, et al. Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma. Front Oncol. 2021;11:678634. https://doi.org/10.3389/fonc.2021.678634
Yan H, Endo Y, Shen Y, Rotstein D, Dokmanovic M, Mohan N, et al. Ado‐trastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce hepatotoxicity. Mol Cancer Ther. 2016;15(3):480–490. https://doi.org/10.1158/1535-7163.MCT-15-0580
Endo Y, Takeda K, Mohan N, Shen Y, Jiang J, Rotstein D, et al. Payload of T‐DM1 binds to cell surface cytoskeleton‐associated protein 5 to mediate cytotoxicity of hepatocytes. Oncotarget. 2018;9(98):37200–37215. https://doi.org/10.18632/oncotarget.26461
Swain SM, Nishino M, Lancaster LH, Li BT, Nicholson AG, Bartholmai BJ, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T‐DXd)‐related interstitial lung disease/pneumonitis‐focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev. 2022;106:102378. https://doi.org/10.1016/j.ctrv.2022.102378
Kumagai K, Aida T, Tsuchiya Y, Kishino Y, Kai K, Mori K. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2‐targeting Ab‐drug conjugate, in monkeys. Cancer Sci. 2020;111(12):4636–4645. https://doi.org/10.1111/cas.14686
Powell CA, Modi S, Iwata H, Takahashi S, Smit EF, Siena S, et al. Pooled analysis of drug‐related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022;7(4):100554. https://doi.org/10.1016/j.esmoop.2022.100554
Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93. https://doi.org/10.1038/s41392-022-00947-7
Bregni G, Galli G, Gevorgyan A, de Braud F, Di Cosimo S. Trastuzumab cardiac toxicity: a problem we put our heart into. Tumori Journal. 2016;102(1):1–5. https://doi.org/10.5301/tj.5000393
Haddley K. Trastuzumab emtansine for the treatment of HER2‐positive metastatic breast cancer. Drugs Today. 2013;49(11):701–715. https://doi.org/10.1358/dot.2013.49.11.2020937
Tarantino P, Modi S, Tolaney SM, Cortés J, Hamilton EP, Kim SB, et al. Interstitial lung disease induced by anti‐ERBB2 antibody‐drug conjugates: a review. JAMA Oncology. 2021;7(12):1873–1881. https://doi.org/10.1001/jamaoncol.2021.3595
Johns AC, Campbell MT. Toxicities from antibody‐drug conjugates. Cancer J. 2022;28(6):469–478. https://doi.org/10.1097/PPO.0000000000000626
None.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.